Skip to main content
PRESCIENT THERAPEUTICS LIMITED logo

PRESCIENT THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PTX ISIN · AU000000PTX3 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,006 across all filing types
Latest filing 2023-10-30 Interim / Quarterly Rep…
Country AU Australia
Listing ASX PTX

About PRESCIENT THERAPEUTICS LIMITED

https://ptxtherapeutics.com/

Prescient Therapeutics Limited is a clinical-stage oncology company focused on developing personalized medicine and innovative cancer treatments. The company leverages two primary technology pillars: modular cell therapies and targeted small molecule inhibitors. Its flagship OmniCAR platform is a universal, multi-arm CAR-T system designed to provide clinicians with enhanced control and flexibility over cell therapy treatments, addressing limitations such as antigen escape and toxicity. Complementing this is the CellPryme platform, which optimizes cell therapy performance through improved manufacturing and efficacy. Additionally, Prescient maintains a pipeline of targeted therapies, including PTX-100, a first-in-class prenylation inhibitor targeting the Ras pathway, and PTX-200, an AKT inhibitor. These programs aim to treat various hematological malignancies and solid tumors by addressing specific genetic drivers of cancer.

Recent filings

Filing Released Lang Actions
September 2023 Quarterly Update and Appendix 4C 12 pages 1.5MB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'September 2023 Activities Report and Appendix 4C' and contains detailed quarterly financial data including cash balances, expenditures, and operational updates. It also discusses clinical trial progress, collaborations, and business development activities. The presence of an Appendix 4C quarterly cash flow statement and the detailed financial and operational narrative indicate this is a comprehensive interim or quarterly report. The document length (15,000 characters) and substantive financial and operational content confirm it is not a brief announcement or a certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2023-10-30 English
PTX results to be presented at world's largest blood meeting 4 pages 1.2MB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Prescient Therapeutics Limited will present Phase 1b cancer trial results at the American Society of Hematology Annual Meeting. It describes the clinical trial, the company's therapies, and the upcoming presentation event. There are no financial statements, detailed financial analysis, or regulatory filings included. The document is an announcement of upcoming clinical trial data presentation rather than the presentation or report itself. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Investor Presentation. It is not a regulatory filing or certification. The content is primarily a corporate announcement about clinical trial results being presented at a conference. Therefore, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2023-10-16 English
Notice of Annual General Meeting/Proxy Form 20 pages 1.4MB
AGM Information Classification · 100% confidence The document is titled 'Notice of Annual General Meeting Explanatory Statement and Proxy Form' and includes detailed information about the upcoming AGM, including date, time, agenda, resolutions to be voted on, proxy voting instructions, and voting exclusions. It does not contain actual financial statements or detailed financial performance data but rather serves as the official notice and explanatory materials for the AGM. The presence of proxy forms, voting instructions, and resolutions to be considered at the AGM clearly identifies this as AGM-related materials. The document length is substantial but it is focused on meeting logistics and shareholder voting rather than financial reporting. Therefore, this document fits the category of AGM Information (AGM-R).
2023-10-12 English
Section 708A Cleansing Notice 2 pages 539.5KB
Capital/Financing Update Classification · 95% confidence The document is a Section 708A Cleansing Notice issued by Prescient Therapeutics Limited, confirming the issuance of shares following the exercise of employee options. It references compliance with the Corporations Act and provides details about the share issue and the company's status as a disclosing entity. There is no financial report, earnings data, or management discussion present. The document is an announcement related to capital issuance and compliance under securities law, specifically about share issuance without disclosure under Part 6D.2 of the Corporations Act. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2023-08-30 English
Application for quotation of securities - PTX 6 pages 28.0KB
Share Issue/Capital Change Classification · 100% confidence The document is an announcement from Prescient Therapeutics Limited regarding the quotation of securities issued due to options being exercised or convertible securities being converted. It details the number and type of securities, issue price, and dates of conversion. The document is structured as an official notification to the ASX (Australian Securities Exchange) about the issuance and quotation of new shares resulting from option exercises. There is no financial report, earnings data, or management discussion present. The content fits the description of a Share Issue/Capital Change announcement, as it relates to new shares being issued and quoted following option exercises.
2023-08-30 English
Appendix 4E and 2023 Annual Report 55 pages 2.5MB
Annual Report Classification · 100% confidence The document is titled 'Prescient Therapeutics Limited Appendix 4E Preliminary final report' and covers the financial year ended 30 June 2023. It includes detailed financial results, company details, directors' report, chair's letter, auditor's report, and consolidated financial statements. The content is comprehensive and includes financial performance, position, and operational review, typical of a full annual report. The presence of an auditor's report and detailed financial statements further confirms this. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. Therefore, this document fits the definition of an Annual Report (10-K). FY 2023
2023-08-24 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.